Safety and Accuracy of Alveoscopy in Interstitial Lung Diseases

Study Overview
=================
Brief Summary
-----------------
Fibered confocal fluorescence microscopy (FCFM), also referred to as Cell-Vizio® (MaunaKea Technologies, France) is a new technique that produces microscopic imaging in a living tissue, through a 1 mm fiberoptic miniprobe that can be introduced into the working channel of the bronchoscope. The system produces real-time imaging of endogenous fluorophores with a 5 µm lateral resolution and a field of view of 600 x 600 µm. FCFM is able to produce dynamic, high-resolution microimaging of the respiratory bronchiolar walls, alveolar ducts and sacs in vivo during endoscopy (a procedure termed as alveoscopy). The hypothesis of this study is that an alveoscopy makes it possible to analyze the microstructure of the distal airways in vivo and to collect specific morphologic information in patients with interstitial lung diseases. The goals of this French Phase II trial are: to evaluate the tolerance of the alveoscopy to describe the normal appearance of the bronchoalveolar system in spontaneous ventilation in normal subjects to describe specific alterations of the bronchoalveolar microstructure in focal or diffuse interstitial lung diseases

Detailed Description
-----------------
The study will include 40 healthy smoker or non-smoker volunteers, 20 patients with normal Chest CT scan and normal respiratory function tests, and 90 patients with focal or diffuse peripheral lung diseases. The Alveoscopy will be performed under local anesthesia, in awake patients during a standard bronchoscopy. The Alveoscopy will be performed on one side of the bronchial tree (left or right lung). Two to ten separate bronchial areas will be explored in each patient, depending on the pathology, focal or diffuse, and the underlying respiratory function. A continuous monitoring of the Oxygen saturation, blood pressure, EKG will be performed during the procedure. A chest X-ray will be performed after the procedure to eliminate a pneumothorax. The morphometric parameters of the alveolar microstructure and their variability will be studied according to the age, gender, lung area explored, smoking status in healthy volunteers and normal CT scan subjects, as well as in patients with peripheral lung diseases.

Official Title
-----------------
Phase II Study of Broncho-Alveoscopy Using Fibered Confocal Fluorescence Microscopy

Conditions
-----------------
Respiratory Tract Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy volunteers: normal chest X-rays and normal lung function tests Patients without parenchymal lung diseases: normal chest computed tomography (CT) scan, normal lung function tests, indication for a bronchoscopy Patients with parenchymal lung disease: indication for a bronchoscopy Written informed consent for the alveoscopy Exclusion Criteria: Bleeding disorders Pulmonary hypertension Contraindication for a bronchoscopy known hypersensitivity to the fluorescent contrast agent (if required)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of lesions localized by confocal endoscopy compared to navigational bronchoscopy |  | time of the confocal endoscopy compared to navigational bronchoscopy | 
| Positive and negative predictive values of confocal signs before and after IV fluorophore injection for the diagnosis of cancer. |  | before and after IV fluorophore injection for the diagnosis of cancer. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bronchoscopy, Diagnostic imaging, Laser scanning confocal microscopy, Pulmonary Alveoli, Healthy volunteers, Diffuse peripheral lung disease, Focal peripheral lung disease